The "Global Tumor Infiltrating Lymphocytes Therapy Market Opportunity, Proprietary Technologies Platforms & Clinical Trials Insight 2030" report has been added to ResearchAndMarkets.com's offering.

This report investigates the current trend of ongoing and emerging clinical trials and identifies the most promising pipeline candidates that have the potential to be next-generation oncology treatments.

Report Finding & Highlights:

• Global & Regional Market Outlook
• Global Tumor Infiltrating Lymphocytes Therapy Market Opportunity: > US$1 Billion
• Number Of Approved Tumor Infiltrating Lymphocytes Therapy: 1 Therapy
• Approved Tumor Infiltrating Lymphocytes Therapy Dosage, Pricing & Sales Insight
• Number Of Tumor Infiltrating Lymphocytes Therapies in Clinical Trials: > 30 Therapies
• Global Tumor Infiltrating Lymphocyte Therapies Clinical Trials By Company, Indication & Phase
• Proprietary Technologies Insight By Companies

This report is intended to give stakeholders a holistic overview of the changing TIL therapy landscape, touching on clinical development, active industry players, technological advancements, and market projections.

Tumor Infiltrating Lymphocytes Therapy Need & Why This Report?

Tumor Infiltrating Lymphocytes Therapy (TIL) therapy has proven to be one of the most promising treatments for solid tumors, particularly in patients who are no longer responsive to conventional treatments like checkpoint inhibitors. In contrast to other conventional immunotherapies, TIL therapy leverages a patient's own tumor infiltrating lymphocytes, already cancer antigen experienced immune cells, to execute a specific, individualized immune response.

This treatment is especially relevant for melanoma and other late-stage cancers when alternatives are exhausted and prognoses unfavorable. Recent US approval in February 2024 of Amtagvi (lifileucel), i.e., the only globally approved TIL therapy to date, has moved commercial interest and scientific impetus in the field ahead at an accelerated pace.

Clinical Trials Insight Included In Report

Data in this section includes specifically trial stages, sponsors, geographical distribution, technology providers, collaborators and license holders. For example, in China, Bennu Biotherapeutics is running a Phase I trial of BEN-101 in solid tumors under the auspices of the Shanghai Jiao Tong University.

In the US, a number of academic institutions and biotechnology companies are conducting early-stage trials extending TIL therapy to indications such as cervical, lung, and head and neck cancers. The data indicate an increasing global interest in TIL research, with the US, China, Australia, and regions of Europe leading trial activity.

Leading Companies Engaged In R&D Of Tumor Infiltrating Lymphocytes Therapy

Apart from Iovance Biotherapeutics, the global standard setter with its lifileucel product, other players such as Juncell Therapeutics (China), Biosyngen (Singapore), SunAct Cancer Institute (India), and Instil Bio (US) are also seriously involved in TIL R&D.

These companies are not merely trying to broaden the therapeutic applications of TIL therapy but also to overcome the several key challenges in scalability, affordability, and access to patients. Academic research hospitals like the National Cancer Centre Singapore and Loma Linda University Cancer Center in the US are also playing active roles through funded pilot programs and institutional partnerships.

Technology Platforms, Collaborations & Agreements

The report indicates a trend towards unified technology platforms that simplify the TIL therapy life cycle. Creative Biolabs, for example, provides an end-to-end platform for the profiling of tumor neoantigens and expansion of TILs. Additionally, Xcell Biosciences Australia has partnered with Royal Perth Hospital to establish an automated production process through the AVATART Foundry system.

Numerous licensing deals and cross-border collaborations are also accelerating innovation, such as the partnership between Malaysia's Abgentil Biomedical and India's SunAct Cancer Institute to localize manufacturing and access.

Report Indicating Future Direction Of Tumor Infiltrating Lymphocytes Therapy Segment

From trial results, company activity, and investment in infrastructure, the report determines that the TIL therapy market is poised for explosive growth. As Amtagvi became the first proven product, the market now is transitioning from academic and experimental to more extensive clinical use and commercialization. Important future trends are shorter manufacturing times, growth into non-melanoma indications, regional manufacturing centers, and middle-income country pricing models.

The coming years are expected to witness a shift from an individual-product market to a multi-player, competitive ecosystem providing various TIL solutions globally.

Key Topics Covered:

1. Tumor Infiltrating Lymphocytes (TIL): A Brief Introduction

1.1 Overview

1.2 TIL History & Concept

2. Emergence Of Tumor Infiltrating Lymphocytes Therapy

2.1 Tumor Infiltrating Lymphocytes As Prognostic Biomarkers

2.2 Tumor Infiltrating Lymphocytes Therapy Combinational Approach

3. Amtagvi - First Approved Tumor Infiltrating Lymphocyte Therapy

3.1 Overview & Patent Insight

3.2 Dosage & Price Analysis

3.3 Sales Analysis

4. Global Tumor Infiltrating Lymphocytes Therapy Market Overview

4.1 Current Market Scenario

4.2 Future Opportunities

5. Tumor Infiltrating Lymphocytes Therapy Development Trends By Region

5.1 US

5.2 Canada

5.3 China

5.4 UK

5.5 EU

6. Tumor Infiltrating Lymphocytes Therapy Approaches By Cancer

6.1 Melanoma

6.2 Lung Cancer

6.3 Breast Cancer

6.4 Gastrointestinal Cancers (Colorectal Cancer, Gastric Cancer, Pancreatic Cancer, Hepatocellular Carcinoma)

6.5 Gynecological Cancers (Ovarian Cancer, Uterine/ Endometrial Cancer, Cervical Cancer)

6.6 Genitourinary Cancers (Bladder/Urothelial Carcinoma, Renal Cell, Prostate Cancer)

6.7 Head & Neck Cancers

6.8 Brain Cancers

7. Global Tumor Infiltrating Lymphocytes Therapy Market Dynamics

7.1 Market Drivers & Opportunities

7.2 Market Challenges & Restraints

8. Global Tumor Infiltrating Lymphocytes Therapy Trials Overview

8.1 By Breakthrough & Fast Track Status

8.2 By Country

8.3 By Company

8.4 By Indication

8.5 By Phase

8.6 By Orphan Status

9. Global Tumor Infiltrating Lymphocyte Therapies Clinical Trials By Company, Indication & Phase

9.1 Research

9.2 Preclinical

9.3 Phase-0

9.4 Phase-I

9.5 Phase-I/II

9.6 Phase-II

9.7 Phase-III

10. Marketed Tumor Infiltrating Lymphocyte Therapies Clinical Pipeline By Company, Indication & Phase

11. Tumor Infiltrating Lymphocytes Therapy Proprietary Technologies Insight By Companies

12. Competitive Landscape

12.1 Adaptimmune

12.2 AgonOx

12.3 GRIT Biotechnology

12.4 ImmuneCyte

12.5 Intima Bioscience

12.6 Iovance Biotherapeutics

12.7 Juncell Therapeutics

12.8 Leman Biotech

12.9 Obsidian Therapeutics

12.10 RootPath

For more information about this report visit https://www.researchandmarkets.com/r/p18bek

About ResearchAndMarkets.com

ResearchAndMarkets.com is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.

View source version on businesswire.com: https://www.businesswire.com/news/home/20251023290989/en/